Ispronicline: Phase II data

Data from the double-blind, placebo-controlled, dose-ranging, U.S. Phase II AAMI trial in 193 subjects showed that 50 mg TC-1734 met all 3 co-primary endpoints in both the per-protocol (PP) and intent...